Yin-Hsun Feng

List of Publications by Citations

Source: https://exaly.com/author-pdf/6539613/yin-hsun-feng-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10 298 4 11 g-index

11 373 1.9 4.07 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
10	Emerging role of microRNA-21 in cancer. <i>Biomedical Reports</i> , 2016 , 5, 395-402	1.8	250
9	Elovl6 is a poor prognostic predictor in breast cancer. <i>Oncology Letters</i> , 2016 , 12, 207-212	2.6	20
8	Oct4 upregulates osteopontin via Egr1 and is associated with poor outcome in human lung cancer. <i>BMC Cancer</i> , 2019 , 19, 791	4.8	14
7	Adiponectin is down-regulated in bone marrow interstitial fluid in hematological malignancy. <i>International Journal of Hematology</i> , 2015 , 102, 312-7	2.3	4
6	Malignant Peripheral Nerve Sheath Tumor of Prostate: A Rare Case Report and Literature Review. <i>Case Reports in Urology</i> , 2016 , 2016, 9317567	0.5	4
5	The Effectiveness of Dignity Therapy as Applied to End-of-Life Patients with Cancer in Taiwan: A Quasi-Experimental Study. <i>Asian Nursing Research</i> , 2020 , 14, 189-195	2.5	2
4	An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e67-74	3.3	1
3	The Expression of MicroRNA-21 in Bone Marrow Fluid is an Indicator of Hematological Disorders and Mortality. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020 , 21, 2817-2821	1.7	1
2	The Expression of MicroRNA-21 in Bone Marrow Fluid is an Indicator of Hematological Disorders and Mortality. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020 , 21, 2817-2821	1.7	1
1	Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy. Journal of Cancer Research and Practice, 2017, 4, 139-142	0.4	